Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.

<h4>Background</h4>To eliminate blinding trachoma, the World Health Organization emphasizes implementing the SAFE strategy, which includes annual mass drug administration (MDA) with azithromycin to the whole population of endemic districts. Prevalence surveys to assess impact at the dist...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jonathan D King, Tesfaye Teferi, Elizabeth A Cromwell, Mulat Zerihun, Jeremiah M Ngondi, Mesele Damte, Frew Ayalew, Zerihun Tadesse, Teshome Gebre, Ayelign Mulualem, Alemu Karie, Berhanu Melak, Mitku Adugna, Demelash Gessesse, Abebe Worku, Tekola Endashaw, Fisseha Admassu Ayele, Nicole E Stoller, Mary Rose A King, Aryc W Mosher, Tesfaye Gebregzabher, Geremew Haileysus, Peter Odermatt, Jürg Utzinger, Paul M Emerson
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
Acceso en línea:https://doaj.org/article/bb9e6d262df1489bb459573c5d76dc5b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bb9e6d262df1489bb459573c5d76dc5b
record_format dspace
spelling oai:doaj.org-article:bb9e6d262df1489bb459573c5d76dc5b2021-11-18T09:16:19ZPrevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.1935-27271935-273510.1371/journal.pntd.0002732https://doaj.org/article/bb9e6d262df1489bb459573c5d76dc5b2014-03-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24625539/pdf/?tool=EBIhttps://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735<h4>Background</h4>To eliminate blinding trachoma, the World Health Organization emphasizes implementing the SAFE strategy, which includes annual mass drug administration (MDA) with azithromycin to the whole population of endemic districts. Prevalence surveys to assess impact at the district level are recommended after at least 3 years of intervention. The decision to stop MDA is based on a prevalence of trachomatous inflammation follicular (TF) among children aged 1-9 years below 5% at the sub-district level, as determined by an additional round of surveys limited within districts where TF prevalence is below 10%. We conducted impact surveys powered to estimate prevalence simultaneously at the sub-district and district in two zones of Amhara, Ethiopia to determine whether MDA could be stopped.<h4>Methodology</h4>Seventy-two separate population-based, sub-district surveys were conducted in 25 districts. In each survey all residents from 10 randomly selected clusters were screened for clinical signs of trachoma. Data were weighted according to selection probabilities and adjusted for correlation due to clustering.<h4>Principal findings</h4>Overall, 89,735 residents were registered from 21,327 households of whom 72,452 people (80.7%) were examined. The prevalence of TF in children aged 1-9 years was below 5% in six sub-districts and two districts. Sub-district level prevalence of TF in children aged 1-9 years ranged from 0.9-76.9% and district-level from 0.9-67.0%. In only one district was the prevalence of trichiasis below 0.1%.<h4>Conclusions/significance</h4>The experience from these zones in Ethiopia demonstrates that impact assessments designed to give a prevalence estimate of TF at sub-district level are possible, although the scale of the work was challenging. Given the assessed district-level prevalence of TF, sub-district-level surveys would have been warranted in only five districts. Interpretation was not as simple as stopping MDA in sub-districts below 5% given programmatic challenges of exempting sub-districts from a highly regarded program and the proximity of hyper-endemic sub-districts.Jonathan D KingTesfaye TeferiElizabeth A CromwellMulat ZerihunJeremiah M NgondiMesele DamteFrew AyalewZerihun TadesseTeshome GebreAyelign MulualemAlemu KarieBerhanu MelakMitku AdugnaDemelash GessesseAbebe WorkuTekola EndashawFisseha Admassu AyeleNicole E StollerMary Rose A KingAryc W MosherTesfaye GebregzabherGeremew HaileysusPeter OdermattJürg UtzingerPaul M EmersonPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 8, Iss 3, p e2732 (2014)
institution DOAJ
collection DOAJ
language EN
topic Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Jonathan D King
Tesfaye Teferi
Elizabeth A Cromwell
Mulat Zerihun
Jeremiah M Ngondi
Mesele Damte
Frew Ayalew
Zerihun Tadesse
Teshome Gebre
Ayelign Mulualem
Alemu Karie
Berhanu Melak
Mitku Adugna
Demelash Gessesse
Abebe Worku
Tekola Endashaw
Fisseha Admassu Ayele
Nicole E Stoller
Mary Rose A King
Aryc W Mosher
Tesfaye Gebregzabher
Geremew Haileysus
Peter Odermatt
Jürg Utzinger
Paul M Emerson
Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
description <h4>Background</h4>To eliminate blinding trachoma, the World Health Organization emphasizes implementing the SAFE strategy, which includes annual mass drug administration (MDA) with azithromycin to the whole population of endemic districts. Prevalence surveys to assess impact at the district level are recommended after at least 3 years of intervention. The decision to stop MDA is based on a prevalence of trachomatous inflammation follicular (TF) among children aged 1-9 years below 5% at the sub-district level, as determined by an additional round of surveys limited within districts where TF prevalence is below 10%. We conducted impact surveys powered to estimate prevalence simultaneously at the sub-district and district in two zones of Amhara, Ethiopia to determine whether MDA could be stopped.<h4>Methodology</h4>Seventy-two separate population-based, sub-district surveys were conducted in 25 districts. In each survey all residents from 10 randomly selected clusters were screened for clinical signs of trachoma. Data were weighted according to selection probabilities and adjusted for correlation due to clustering.<h4>Principal findings</h4>Overall, 89,735 residents were registered from 21,327 households of whom 72,452 people (80.7%) were examined. The prevalence of TF in children aged 1-9 years was below 5% in six sub-districts and two districts. Sub-district level prevalence of TF in children aged 1-9 years ranged from 0.9-76.9% and district-level from 0.9-67.0%. In only one district was the prevalence of trichiasis below 0.1%.<h4>Conclusions/significance</h4>The experience from these zones in Ethiopia demonstrates that impact assessments designed to give a prevalence estimate of TF at sub-district level are possible, although the scale of the work was challenging. Given the assessed district-level prevalence of TF, sub-district-level surveys would have been warranted in only five districts. Interpretation was not as simple as stopping MDA in sub-districts below 5% given programmatic challenges of exempting sub-districts from a highly regarded program and the proximity of hyper-endemic sub-districts.
format article
author Jonathan D King
Tesfaye Teferi
Elizabeth A Cromwell
Mulat Zerihun
Jeremiah M Ngondi
Mesele Damte
Frew Ayalew
Zerihun Tadesse
Teshome Gebre
Ayelign Mulualem
Alemu Karie
Berhanu Melak
Mitku Adugna
Demelash Gessesse
Abebe Worku
Tekola Endashaw
Fisseha Admassu Ayele
Nicole E Stoller
Mary Rose A King
Aryc W Mosher
Tesfaye Gebregzabher
Geremew Haileysus
Peter Odermatt
Jürg Utzinger
Paul M Emerson
author_facet Jonathan D King
Tesfaye Teferi
Elizabeth A Cromwell
Mulat Zerihun
Jeremiah M Ngondi
Mesele Damte
Frew Ayalew
Zerihun Tadesse
Teshome Gebre
Ayelign Mulualem
Alemu Karie
Berhanu Melak
Mitku Adugna
Demelash Gessesse
Abebe Worku
Tekola Endashaw
Fisseha Admassu Ayele
Nicole E Stoller
Mary Rose A King
Aryc W Mosher
Tesfaye Gebregzabher
Geremew Haileysus
Peter Odermatt
Jürg Utzinger
Paul M Emerson
author_sort Jonathan D King
title Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
title_short Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
title_full Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
title_fullStr Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
title_full_unstemmed Prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
title_sort prevalence of trachoma at sub-district level in ethiopia: determining when to stop mass azithromycin distribution.
publisher Public Library of Science (PLoS)
publishDate 2014
url https://doaj.org/article/bb9e6d262df1489bb459573c5d76dc5b
work_keys_str_mv AT jonathandking prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT tesfayeteferi prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT elizabethacromwell prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT mulatzerihun prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT jeremiahmngondi prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT meseledamte prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT frewayalew prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT zerihuntadesse prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT teshomegebre prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT ayelignmulualem prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT alemukarie prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT berhanumelak prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT mitkuadugna prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT demelashgessesse prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT abebeworku prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT tekolaendashaw prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT fissehaadmassuayele prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT nicoleestoller prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT maryroseaking prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT arycwmosher prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT tesfayegebregzabher prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT geremewhaileysus prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT peterodermatt prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT jurgutzinger prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
AT paulmemerson prevalenceoftrachomaatsubdistrictlevelinethiopiadeterminingwhentostopmassazithromycindistribution
_version_ 1718420925288808448